YinQiSanHuang Jiedu decoction for the treatment of hepatitis B-related compensated liver cirrhosis: study protocol for a multi-center randomized controlled trial
This study aims to test the integrative medicine (Chinese medicine plus antiviral therapy) effective on lowing hepatocellular carcinoma risk among patients with hepatitis-related compensated liver cirrhosis.Methods and analysisThis is a multi-center randomized controlled trial, and a total of 5 hospitals and 802 patients will be involved in. All the subjects are randomly allocated to the YinQiSanHuang Jiedu decoction (YQSHD) group (n = 401) or the placebo group (n = 401). The YQSHD group receives YQSHD granule with entecavir (ETV), and the placebo group receives YQSHD placebo with ETV. The treatment period will last for 52...
Source: Trials - October 14, 2021 Category: Research Source Type: clinical trials
Therapy Strategies After LAA Occluder Device Embolization
Conditions: Left Atrial Appendage Occluder; Device Embolisation; Therapy Strategies; Risk Factors Intervention: Procedure: Removal or leaving of LAA occluders Sponsors: Cardiovascular Center Frankfurt; Kerstin Piayda, CardioVascular Center Frankfurt, Frankfurt, Germany; Kolja Sievert, CardioVascular Center Frankfurt, Frankfurt, Germany; Roberto Galea, Universitätsspital Bern, Bern, Switzerland; Moniek Maarse, St. Antonius Ziekenhuis, Nieuwegein, Netherlands; Ainars Rudzitis, P. Stradins Clinical University Hospital, Riga, Lettland; Jacob Pontoppidan, Odense University Hosp...
Source: ClinicalTrials.gov - August 20, 2021 Category: Research Source Type: clinical trials
